These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 23410901)

  • 1. Successful EGFR-TKI rechallenge of leptomeningeal carcinomatosis after gefitinib-induced interstitial lung disease.
    Nakamichi S; Kubota K; Horinouchi H; Kanda S; Fujiwara Y; Nokihara H; Yamamoto N; Tamura T
    Jpn J Clin Oncol; 2013 Apr; 43(4):422-5. PubMed ID: 23410901
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Successful erlotinib rechallenge for leptomeningeal metastases of lung adenocarcinoma after erlotinib-induced interstitial lung disease: a case report and review of the literature.
    Togashi Y; Masago K; Hamatani Y; Sakamori Y; Nagai H; Kim YH; Mishima M
    Lung Cancer; 2012 Aug; 77(2):464-8. PubMed ID: 22579408
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Successful treatment with erlotinib after gefitinib-induced interstitial lung disease: a case report and literature review.
    Koma Y; Matsuoka H; Yoshimatsu H; Suzuki Y
    Int J Clin Pharmacol Ther; 2012 Oct; 50(10):760-4. PubMed ID: 22853866
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Erlotinib efficacy and cerebrospinal fluid concentration in patients with lung adenocarcinoma developing leptomeningeal metastases during gefitinib therapy.
    Masuda T; Hattori N; Hamada A; Iwamoto H; Ohshimo S; Kanehara M; Ishikawa N; Fujitaka K; Haruta Y; Murai H; Kohno N
    Cancer Chemother Pharmacol; 2011 Jun; 67(6):1465-9. PubMed ID: 21274533
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Promising Effects of Afatinib on Leptomeningeal Carcinomatosis Derived from Erlotinib-resistant Lung Adenocarcinoma.
    Sekine A; Kato T; Iwasawa T; Baba T; Suido A; Sakuranaka H; Futaki M; Ogura T
    Intern Med; 2016; 55(17):2457-61. PubMed ID: 27580550
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Erlotinib versus gefitinib for control of leptomeningeal carcinomatosis in non-small-cell lung cancer.
    Lee E; Keam B; Kim DW; Kim TM; Lee SH; Chung DH; Heo DS
    J Thorac Oncol; 2013 Aug; 8(8):1069-74. PubMed ID: 23804027
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [A case of lung adenocarcinoma with coexisting G719X and T790M EGFR mutations in which erlotinib was effective for the treatment of leptomeningeal carcinomatosis].
    Katono K; Kasajima M; Ishihara M; Hayashi N; Nagashima Y; Igawa S; Masuda N
    Gan To Kagaku Ryoho; 2013 Mar; 40(3):375-7. PubMed ID: 23507602
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gefitinib successfully administered in a lung cancer patient with leptomeningeal carcinomatosis after erlotinib-induced pneumatosis intestinalis.
    Uruga H; Moriguchi S; Takahashi Y; Ogawa K; Murase K; Mochizuki S; Hanada S; Takaya H; Miyamoto A; Morokawa N; Kishi K
    BMC Cancer; 2018 Aug; 18(1):825. PubMed ID: 30115025
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Erlotinib in combination with pemetrexed/cisplatin for leptomeningeal metastases and cerebrospinal fluid drug concentrations in lung adenocarcinoma patients after gefitinib faliure.
    Yang H; Yang X; Zhang Y; Liu X; Deng Q; Zhao M; Xu X; He J
    Target Oncol; 2015 Mar; 10(1):135-40. PubMed ID: 24985049
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Retrospective analysis of survival in patients with leptomeningeal carcinomatosis from lung adenocarcinoma treated with erlotinib and gefitinib.
    Kashima J; Okuma Y; Miwa M; Hosomi Y
    Jpn J Clin Oncol; 2017 Apr; 47(4):357-362. PubMed ID: 28064206
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Successful rechallenge with erlotinib in a patient with EGFR-mutant lung adenocarcinoma who developed gefitinib-related interstitial lung disease.
    Fukui T; Otani S; Hataishi R; Jiang SX; Nishii Y; Igawa S; Mitsufuji H; Kubota M; Katagiri M; Masuda N
    Cancer Chemother Pharmacol; 2010 Mar; 65(4):803-6. PubMed ID: 20035424
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Satisfactory outcome with erlotinib after failure with gefitinib in a patient with meningeal carcinomatosis secondary to non-small cell lung cancer].
    Fujikura Y; Morishima Y; Ota K; Otsuka S; Homma S; Kurishima K; Hizawa N
    Nihon Kokyuki Gakkai Zasshi; 2010 May; 48(5):391-6. PubMed ID: 20560443
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interstitial lung disease following erlotinib (Tarceva) in a patient who previously tolerated gefitinib (Iressa).
    Tammaro KA; Baldwin PD; Lundberg AS
    J Oncol Pharm Pract; 2005 Sep; 11(3):127-30. PubMed ID: 16390601
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Erlotinib for pretreated squamous cell carcinoma of the lung in Japanese patients.
    Hata A; Katakami N; Kunimasa K; Yoshioka H; Fujita S; Kaji R; Tachikawa R; Tomii K; Imai Y; Iwasaku M; Ishida T
    Jpn J Clin Oncol; 2011 Dec; 41(12):1366-72. PubMed ID: 22058419
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activity of pemetrexed and high-dose gefitinib in an EGFR-mutated lung adenocarcinoma with brain and leptomeningeal metastasis after response to gefitinib.
    Yuan Y; Tan C; Li M; Shen H; Fang X; Hu Y; Ma S
    World J Surg Oncol; 2012 Nov; 10():235. PubMed ID: 23134665
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High-dose, pulsatile erlotinib in two NSCLC patients with leptomeningeal metastases--one with a remarkable thoracic response as well.
    Kuiper JL; Smit EF
    Lung Cancer; 2013 Apr; 80(1):102-5. PubMed ID: 23375403
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized phase II study of gefitinib versus erlotinib in patients with advanced non-small cell lung cancer who failed previous chemotherapy.
    Kim ST; Uhm JE; Lee J; Sun JM; Sohn I; Kim SW; Jung SH; Park YH; Ahn JS; Park K; Ahn MJ
    Lung Cancer; 2012 Jan; 75(1):82-8. PubMed ID: 21684626
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical Efficacy of Afatinib Treatment for a Patient with Leptomeningeal Carcinomatosis.
    Kawaguchi Y; Hanaoka J; Hayashi H; Mizusaki N; Iihara H; Itoh Y; Sugiyama T
    Chemotherapy; 2017; 62(3):147-150. PubMed ID: 28030859
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epidermal growth factor receptor tyrosine kinase inhibitors as a first-line therapy for never-smokers with adenocarcinoma of the lung having asymptomatic synchronous brain metastasis.
    Kim JE; Lee DH; Choi Y; Yoon DH; Kim SW; Suh C; Lee JS
    Lung Cancer; 2009 Sep; 65(3):351-4. PubMed ID: 19157632
    [TBL] [Abstract][Full Text] [Related]  

  • 20. EGFR-TKI and lung adenocarcinoma with CNS relapse: interest of molecular follow-up.
    Ruppert AM; Beau-Faller M; Neuville A; Guerin E; Voegeli AC; Mennecier B; Legrain M; Molard A; Jeung MY; Gaub MP; Oudet P; Quoix E
    Eur Respir J; 2009 Feb; 33(2):436-40. PubMed ID: 19181917
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.